Advances in cancer therapy have dramatically contributed to the decline in breast cancer deaths over the last three decades. But even with these advances, drug resistance—when tumors stop responding to anti-cancer drugs—remains a serious clinical challenge. Dr. Sarat Chandarlapaty talks about the strategies to prevent cancer cells from evading the drugs designed to kill them. 

Dr. Chandarlapaty is a laboratory head at the Human Oncology and Pathogenesis Program at the Memorial Sloan Kettering Cancer Center. He's also a BCRF Scientific Advisory Board member and has been a BCRF researcher since 2015.